clinical trial · NCT06423703
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
Tris Pharma, Inc.·phase3·completed·n = 240
Acute PainCebranopadolOxycodone IRPlacebo OnlyPlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.
started
Jul 18, 2024
primary completion
Jan 31, 2025
completion
Jan 31, 2025
last updated
Jan 26, 2026
detailed description
This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled parallel-group study to evaluate the efficacy and safety of cebranopadol in the treatment of postoperative pain following primary unilateral bunionectomy with first metatarsal osteotomy. The study will be conducted in 3 phases: Screening, Treatment, and Follow-up.
official title
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain After Primary Unilateral Bunionectomy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol